Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Grail

Stock Market Today: Dow Jones Up But Nvidia Falls On New China Threat; Cathie Wood Loads Up On This Stock Amid 76% Dive (Live Coverage)

The Dow Jones rose on the stock market today. Treasury Secretary Bessent spoke out on China. Some Warren Buffett stocks are near entries.

Investors Business Daily

Canyon Grail CF SLX 8 AXS review: A gravel race bike that can do it all

The Canyon Grail CF SLX is a rapid gravel race bike that can do everything well

Cycling News

GRAIL Scores Relative Strength Rating Upgrade; Hits Key Benchmark

GRAIL shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 83.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Showing Improving Market Leadership: GRAIL Earns 83 RS Rating

GRAIL sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

GRAIL: Biotech Stock Targeting $100B Cancer Market

GRAIL is a small biotech stock on the rise big time recently. Its innovative technology gives it the opportunity to capitalize on a massive addressable market.

MarketBeat

One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's

Garmin stock, along with Ollie's Bargain Outlet, are among the best stocks to watch on the stock market today.

Investors Business Daily

Canyon Grail CF SL 7 AXS review: a gravel bike of two halves?

The integrated cockpit and aero tubing are somewhat at odds with the Grail's taller stack height

Cycling Weekly

Read news from The Economist, FT, and more,
with one subscription

GRAIL Getting Closer To Key Technical Benchmark

A Relative Strength Rating upgrade for GRAIL shows improving technical performance. Will it continue?

Investors Business Daily

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

StockNews.com

The Canyon Grail CF SLX 8 AXS is one of the best gravel bikes I have ever tested but I would never buy one

Canyon’s Grail is an optimized gravel racing machine, but is it the pinnacle of gravel tech or death by integration?

Bike Perfect

What You Need to Know Ahead of Illumina's Earnings Release

Illumina is expected to release its second-quarter earnings next month, analysts expect a double-digit earnings dip.

Barchart

3 Biopharma Stocks to Buy for Long-Term Growth

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

StockNews.com

3 Biotech Stocks to Monitor for May Moves

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

StockNews.com

'You Know You’ve Still Got To Go Through Hell To Get There, But If You Can Get It At Stage 2 or 3'... Hall Of Famer Juli Inkster On New Cancer Screening

Are we entering a new worldwide era for cancer screening?

Golf Monthly

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Illumina Ends Its Controversial Grail Battle With A Divestiture; Shares Rise

Illumina stock rose Monday after the company said it would divest its cancer detection outfit, Grail, following a lengthy court battle.

Investors Business Daily

Illumina To Sell Grail After U.S. Antitrust Ruling

Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws,

Top News

Illumina Sheds Light, Divests its Cancer Tester, Grail

Illumina, a beacon in genetic science, is set to unfurl its stake in Grail-the stellar creator of cancer-detecting tests–in a dance of corporate divestiture.

StockNews.com

3 Healthcare Stocks to Buy With Major Value Behind Them

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the integration of advanced technologies in offerings and operations. Therefore, it could be wise to buy fundamentally strong medical stocks HCA Healthcare (HCA), LifeVantage (LFVN), and Semler Scientific (SMLR). Read more….

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

DNA-Reading Giant Illumina Crashes As Macro Pressures Guidance — Again

Illumina stock crashed Friday after the DNA-reading behemoth slashed its outlook as pressures continue to build on life sciences companies.

The Independent UK

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

Fortune

Inside Illumina’s bruising proxy battle with billionaire activist investor Carl Icahn

Illumina’s contentious acquisition of cancer test maker Grail brought billionaire Carl Icahn to the company’s doorstep.

The Independent UK

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog

Businessweek

Illumina’s Sudden CEO Exit Is Just One of Many Problems Facing DNA Company

The sudden resignation of Francis deSouza raises questions about the firm’s future after its proxy fight with Carl Icahn.

Fortune

Carl Icahn’s activist play plays into the hands of Lina Khan and EU regulators

Every company with acquisition plans in the U.S. and Europe should be concerned about the FTC partnering with EU regulators to sink the Illumina-Grail deal.

Bike Perfect

Canyon Grail CF SL 7 eTap review – gravel bike with a need for speed

We put one of Canyon's fast and light gravel bikes to the test and see how it rides outside its comfort zone

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations